Rabeprazole 20 mg
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Gastroesophageal Reflux Disease
Conditions
Gastroesophageal Reflux Disease
Trial Timeline
Oct 1, 2004 → Jun 1, 2008
NCT ID
NCT00165841About Rabeprazole 20 mg
Rabeprazole 20 mg is a phase 2 stage product being developed by Eisai for Gastroesophageal Reflux Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT00165841. Target conditions include Gastroesophageal Reflux Disease.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00165841 | Phase 2 | Completed |
Competing Products
20 competing products in Gastroesophageal Reflux Disease